7xm moto
2025-01-11   

7xm moto Microsoft 365 Copilot Will Reportedly Stop Using OpenAI Models Exclusively

Freelance photographer arrested on Capitol riot charges

Tasmania’s $1 billion salmon industry will supply thousands of Australian households this Christmas, its fresh and smoked fish fillets a relatively cheap alternative to many seafood options. But what is the environmental cost? Salmon farming in Tasmania. Credit: Adam Gibson Tasmania’s big three salmon producers – foreign-owned companies Huon, Tassal and Petuna – promote the industry as sustainable, with low environmental impacts. But the industry’s critics warn it is poorly regulated, environmentally harmful and expanding at an unsustainable pace. Seafood shoppers face a difficult task in deciding who to trust, especially with political leaders gearing up for an election stoush over the future of the industry. Fishy issues Salmon farms have been blamed for environmental degradation around the Tasmanian coastline, antibiotics leaking into the food chain, algal blooms, dead seals and introduction of hundreds of thousands of escapee fish into the environment. However, Salmon Tasmania chief executive Luke Martin, who heads the peak body for the industry, said the farms were a good fit for the Tasmanian environment. “We know millions of Australians will have salmon on the menu this Christmas lunch, and by doing so, they are supporting the livelihoods of 5000 Australians living across regional Tasmanian communities,” Martin said. “Salmon is also a responsibly sourced seafood farmed under the highest environmental regulatory conditions of any farmed protein in Australia. “Aquaculture also eases demand pressure on our wild fishing stocks.” A salmon farm in Tasmania. Credit: Getty Images/iStockphoto Salmon Tasmania’s website states the regulations strike a balance between growing a vital protein source, which is produced with minimal environmental impacts due to careful management. The industry states its physical footprint on the water is 4000 hectares, compared to 426 million for agriculture on land. “Tasmanian waterways are not, and never can be, overrun by salmon pens,” it said. Green gripes However, environmental groups paint a different picture. “The industry puts into the sea more pollutants than all of Tasmania’s sewage outfalls combined,” said Australian Marine Conservation Society sustainable seafood program manager Adrian Meder. The organisation’s GoodFish sustainable seafood guide told shoppers to reject Tasmanian farmed salmon this Christmas, warning that the huge expansion of the industry’s footprint “could lead to high environmental impacts”. Wild fish kilometres from salmon farms have been found with antibiotic residue in their flesh. There are strict health guidelines around food containing antibiotics, due to the potential for uncontrolled use to lead to the creation of so-called superbugs in the human population. Farmed salmon are sometimes treated with antibiotics to prevent infections that can kill fish or hurt production levels. The Salmon Tasmania website said only its veterinarians can prescribe antibiotics. Meder said nutrient-rich salmon waste is churned out from salmon pens, disrupting the marine ecosystem. It has been linked to algal blooms that have, in some instances, clogged inshore reefs in several locations near farms. A Tasmanian parliamentary inquiry completed in 2022 warned that the industry’s rapid growth had been facilitated by the state government, which is “an enthusiastic promoter and supporter of the industry”. It included several scientific expert submissions that warned about algal outbreaks and issued a recommendation for “ceasing operations in sensitive, sheltered and biodiverse areas” – a call Meder said had been ignored. Salmon Tasmania rejected these claims. “We do not know who the Australian Marine Conservation Society is, what their agenda is, or who funds them, but we are very confident in the sustainability of our operations across Tasmania,” Martin said. Harbouring doubts Macquarie Harbour on Tasmania’s west coast is not the main source of salmon supply, producing around 13 per cent of annual production. But it is where the most controversial leases are, because it is the only home for the incredibly rare and ancient relic, the Maugean skate, of which there are only 40 to 120 adults left in the wild. Salmon farming began there in the late 1980s, and all three of Tasmania’s salmon companies, Tassal, Huon and Petuna, operate in the waterway. They have recently scaled back the size of their operations as concerns about the industry’s impact on the critically endangered fish grew. The federal government’s threatened species committee said in August the best way to save the endangered fish was to eliminate, or at least dramatically cut back on, salmon farming in its habitat. The committee said there was a “significant correlation” between low oxygen levels and an increase in salmon farming. Farmed fish suck up a lot of the oxygen in the water, while fish food and faeces that enter the water via the salmon pens feed oxygen-consuming bacteria. Salmon farmers are trialling mechanical systems that push micro bubbles of oxygen to the bottom of the harbour. “No fish farming should ever pose an extinction threat to an endangered species, and no other fish farming industry in Australia does,” Meder said. “It’s actually really easy to do fish farming better than this.” Salmon Tasmania has warned that scaling back the industry could cut the 260 local jobs that it generates and claimed that multiple factors affected water quality, not just farming, including climate change and disruption from hydroelectric dams to river flows into Macquarie Harbour. Political fallout Federal Environment Minister Tanya Plibersek has on her desk a request from environment groups to revoke licences for farming in Macquarie Harbour, but a decision is not expected before an election due by May. Opposition Leader Peter Dutton has accused the government of seeking to shut down the salmon industry. “The government’s prepared to hang the local community out to dry,” he said this month. Macquarie Harbour is in the Braddon electorate, which the Liberal Party won from Labor at the 2019 election. Prime Minister Anthony Albanese has hopes to win Braddon back. He visited on December 14 and declared he would not pre-empt Plibersek’s legal responsibilities as environment minister, but nevertheless guaranteed the industry would continue under his leadership. Prime Minister Anthony Albanese visits salmon farms in Macquarie Harbour, on Tasmania’s west coast. “As long as I’m prime minister, there will be support for jobs here in Tasmania because I understand how important it is for the Tasmanian economy,” Albanese declared. Plibersek was absent from his visit. However, Plibersek said on December 19 that she welcomed the prime minister’s presence in Tasmania and echoed his support for the industry. But it was far harder to interpret her position on the future of the industry, which she said must be weighed against environmental concerns. “We know that the salmon industry is important for local jobs in Tasmania, but we also know that Tasmanians really value their natural environment ... I’m not going to comment on any decision that is before me at the moment.” Cut through the noise of federal politics with news, views and expert analysis. Subscribers can sign up to our weekly Inside Politics newsletter .

COLLEGE BOWL

Dublin, Dec. 23, 2024 (GLOBE NEWSWIRE) -- The "Burkitt Lymphoma - Global Clinical Trials Review, 2024" has been added to ResearchAndMarkets.com's offering. The clinical trial report provides an overview of Burkitt Lymphoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Burkitt Lymphoma. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. The clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Report Scope The report provides a snapshot of the global clinical trials landscape Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment The Report provides enrollment trends for the past five years Report provides latest news for the past three months Reasons to Buy Assists in formulating key business strategies with regards to investment Helps in identifying prominent locations for conducting clinical trials which saves time and cost Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities Supports understanding of trials count and enrollment trends by country in global therapeutics market Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials Facilitates clinical trial assessment of the indication on a global, regional and country level Key Topics Covered: Clinical Trials Report Coverage Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Five Countries Contributing to Clinical Trials in Asia-Pacific Top Five Countries Contributing to Clinical Trials in Europe Top Countries Contributing to Clinical Trials in North America Top Five Countries Contributing to Clinical Trials in Middle East and Africa Top Countries Contributing to Clinical Trials in Central and South America Clinical Trials by G7 Countries: Proportion of Burkitt Lymphoma to Oncology Clinical Trials Clinical Trials by Phase in G7 Countries Clinical Trials in G7 Countries by Trial Status Clinical Trials by E7 Countries: Proportion of Burkitt Lymphoma to Oncology Clinical Trials Clinical Trials by Phase in E7 Countries Clinical Trials in E7 Countries by Trial Status Clinical Trials by Phase In Progress Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Subjects Recruited Over a Period of Time Clinical Trials by Sponsor Type Prominent Sponsors Top Companies Participating in Burkitt Lymphoma Therapeutics Clinical Trials Prominent Drugs Clinical Trial Profile Snapshots Abbreviations Company Coverage: Bristol-Myers Squibb Co Pfizer Inc Takeda Pharmaceutical Co Ltd Roche Holding AG Amgen Inc Gilead Sciences Inc Merck & Co Inc Novartis AG Sanofi Sian Wuhan Medical Technology Co Ltd For more information about this clinical trials report visit https://www.researchandmarkets.com/r/c5m5c6 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.Noodles and wine are the secret ingredients for a strange new twist in China's doping sagaTrump taps forceful ally of hard-line immigration policies to head Customs and Border Protection

Trump voices support for Hegseth, says he's "doing very well" President-elect Donald Trump took to social media Friday to defend his embattled pick for secretary of defense, Pete Hegseth. CBS News political reporter Olivia Rinaldi has the latest on Hegseth's effort to be confirmed for the job.

Biden is considering preemptive pardons for officials and allies before Trump takes office

Medtronic (NYSE:MDT) Given New $97.00 Price Target at Sanford C. Bernstein

Microsoft is reportedly looking to reduce its reliance on OpenAI for the AI models powering its Microsoft 365 Copilot assistant. Citing cost and speed concerns, reported yesterday that Microsoft is developing in-house, smaller AI models to make its flagship AI assistant more efficient. The company is also said to be looking at third-party AI models to diversify the technology behind Microsoft 365 Copilot. “In addition to training its own smaller models including the latest Phi-4, Microsoft is also working to customize other open-weight models to make 365 Copilot faster and more efficient,” Reuters said citing sources familiar with the efforts. “The goal is to make it less expensive for Microsoft to run 365 Copilot, and potentially pass along those savings to the end customer, one of the sources said.” Sign up for our new free newsletter to get three time-saving tips each Friday — get free copies of Paul Thurrott's Windows 11 and Windows 10 Field Guides (normally $9.99) as a special welcome gift! In recent years, Microsoft invested billions of dollars into OpenAI to get an exclusive license to use and customize OpenAI’s GPT-4 model, which powers its Microsoft 365 Copilot offering for commercial customers. The AI assistant is priced at $30 per user per month on top of a qualifying Microsoft 365 plan, and it’s integrated into various Microsoft 365 apps. Organizations can also add agents to Copilot to automate business processes. In a statement shared with Reuters, a Microsoft spokesperson said “We incorporate various models from OpenAI and Microsoft depending on the product and experience.” The company also said that OpenAI remains Microsoft’s main partner to work on the most advanced AI models coming to the market. While Microsoft’s partnership with OpenAI allowed the company to get its hands on cutting-edge AI models, the earlier this year probably in an increasingly complex relationship. Led by DeepMind and Inflection co-founder Mustafa Suleyman, this new AI division is now developing proprietary AI models. The that Microsoft launched in October actually uses a combination of in-house AI models and OpenAI models. According to Reuters, Microsoft CEO Satya Nadella and other Microsoft leaders are keeping a close eye on the company’s efforts to reduce its reliance on OpenAI. In addition to the consumer version of Microsoft Copilot no longer relying as much on OpenAI technology, Microsoft also announced in October that GitHub Copilot was . At the time, the company acknowledged that developers should be able to “decide which models work best for them.” Laurent is a Senior News Editor at Thurrott.com. He's been writing about the tech industry for many years and his favorite topics to cover include Big Tech, media, and gaming. He was also the former Editorial Manager of the from 2022 to 2023. Join the crowd where the love of tech is real - become a Thurrott Premium Member today! Sign up for our new free newsletter to get three time-saving tips each Friday

Related hot word search:

Previous: 7xm login register download philippines
Next: 7xm movies download